IMV Schwankungsanfälligkeit
Was ist das Schwankungsanfälligkeit von IMV?
Schwankungsanfälligkeit von IMV, Inc. ist 0.00%
Was ist die Definition von Schwankungsanfälligkeit?
Die Schwankungsanfälligkeit oder Prozent des durchschnittlichen wahren Bereichs (ATRP 14) ist die ATR, ausgedrückt als Prozentsatz des Schlusskurses.
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
Schwankungsanfälligkeit von Unternehmen in Health Care Sektor auf TSX im Vergleich zu IMV
Was macht IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Unternehmen mit schwankungsanfälligkeit ähnlich IMV
- IMV hat Schwankungsanfälligkeit von 0.00%
- Laboratoire les 3 Chenes hat Schwankungsanfälligkeit von 0.01%
- Kyckr hat Schwankungsanfälligkeit von 0.01%
- Rousselet Centrifugation S.A hat Schwankungsanfälligkeit von 0.01%
- U&I Learning NV hat Schwankungsanfälligkeit von 0.01%
- UBS ETF SICAV - MSCI United Kingdom 100% hedged to CHF UCITS ETF hat Schwankungsanfälligkeit von 0.01%
- Bagir hat Schwankungsanfälligkeit von 0.01%